SARS-CoV-2 mRNA-based vaccine in hemodialysis patients : a single center-experience
Copyright by Società Italiana di Nefrologia SIN, Rome,Italy..
Hemodialysis patients have an increased risk of severe complications when infected with SARS-CoV-2. The introduction of the SARS-CoV-2 vaccine represented an important progress in limiting severe forms of the disease. The focus of our study is the detection of the antibody titer in chronic hemodialysis patients vaccinated with the mRNA vaccine BNT162b2 (Comirnaty, Pfizer-BioNTech). The antibody titers were measured in 57 hemodialysis patients, vaccinated with 3 doses according to ministerial criteria, by ElectroChemiLuminescence ImmunoAssay (ECLIA). The response was defined as an antibody titer above the dosable level > 0,8 UI/ml. A good antibody response was defined as titer > 250 UI/ml. Infections with SARS-CoV-2 and adverse effects to the vaccine were recorded. Our study showed in 93% of the hemodialysis patients a dosable antibody response after the second dose of the vaccine. After the third dose of the vaccine, 100% of the hemodialysis patients reached a dosable antibody titer. The vaccine proved to be safe, no serious adverse events were observed. After the third dose, SARS-CoV-2 infections were still observed, but with reduced severity. A vaccination course against SARS-CoV-2 infection with three doses of BNT162b2 in the dialysis patient is associated with a good immune response and protects against severe infections.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
|---|---|
| Enthalten in: |
Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia - 40(2023), 3 vom: 29. Juni |
| Sprache: |
Italienisch |
|---|
| Beteiligte Personen: |
Bonell, Vera [VerfasserIn] |
|---|
| Themen: |
BNT162 Vaccine |
|---|
| Anmerkungen: |
Date Completed 12.07.2023 Date Revised 18.07.2023 published: Electronic Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM359289509 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359289509 | ||
| 003 | DE-627 | ||
| 005 | 20231226080544.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||ita c | ||
| 028 | 5 | 2 | |a pubmed24n1197.xml |
| 035 | |a (DE-627)NLM359289509 | ||
| 035 | |a (NLM)37427909 | ||
| 035 | |a (PII)2023-vol3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ita | ||
| 100 | 1 | |a Bonell, Vera |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SARS-CoV-2 mRNA-based vaccine in hemodialysis patients |b a single center-experience |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.07.2023 | ||
| 500 | |a Date Revised 18.07.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright by Società Italiana di Nefrologia SIN, Rome,Italy. | ||
| 520 | |a Hemodialysis patients have an increased risk of severe complications when infected with SARS-CoV-2. The introduction of the SARS-CoV-2 vaccine represented an important progress in limiting severe forms of the disease. The focus of our study is the detection of the antibody titer in chronic hemodialysis patients vaccinated with the mRNA vaccine BNT162b2 (Comirnaty, Pfizer-BioNTech). The antibody titers were measured in 57 hemodialysis patients, vaccinated with 3 doses according to ministerial criteria, by ElectroChemiLuminescence ImmunoAssay (ECLIA). The response was defined as an antibody titer above the dosable level > 0,8 UI/ml. A good antibody response was defined as titer > 250 UI/ml. Infections with SARS-CoV-2 and adverse effects to the vaccine were recorded. Our study showed in 93% of the hemodialysis patients a dosable antibody response after the second dose of the vaccine. After the third dose of the vaccine, 100% of the hemodialysis patients reached a dosable antibody titer. The vaccine proved to be safe, no serious adverse events were observed. After the third dose, SARS-CoV-2 infections were still observed, but with reduced severity. A vaccination course against SARS-CoV-2 infection with three doses of BNT162b2 in the dialysis patient is associated with a good immune response and protects against severe infections | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a ElectroChemiLuminescence ImmunoAssay (ECLIA) | |
| 650 | 4 | |a Hemodialysis patients | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a mRNA vaccine BNT162b2 | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a BNT162 Vaccine |2 NLM | |
| 650 | 7 | |a RNA, Messenger |2 NLM | |
| 700 | 1 | |a Mongera, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Passler, Werner |e verfasserin |4 aut | |
| 700 | 1 | |a Bonincontro, Maria Luisa |e verfasserin |4 aut | |
| 700 | 1 | |a Tabbì, Maria Grazia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia |d 1997 |g 40(2023), 3 vom: 29. Juni |w (DE-627)NLM093699778 |x 1724-5990 |7 nnns |
| 773 | 1 | 8 | |g volume:40 |g year:2023 |g number:3 |g day:29 |g month:06 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 40 |j 2023 |e 3 |b 29 |c 06 | ||